GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. It recently won approval for a non-opioid pain ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $475.49, marking a -1.41% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 3.46%.

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

The US$498 analyst price target for VRTX is 38% less than our estimate of fair value Does the April share price for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reflect what it's really worth?

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $484.01 ... At the same time, the Dow lost 3.98%, and the tech-heavy Nasdaq lost 5.97%. Shares of the drugmaker witnessed ...

Equity markets may be struggling because of President Donald Trump's current economic policies, but that doesn't mean ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...